Pim A L Tonino Selected Research

Thrombosis (Thrombus)

1/2023	Titanium-Nitride-Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome: 5-Year Clinical Outcomes of the TIDES-ACS Randomized Clinical Trial.
8/2022	Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.
1/2021	Safety of Selective Intracoronary Hypothermia During Primary Percutaneous Coronary Intervention in Patients With Anterior STEMI.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pim A L Tonino Research Topics

Disease

12	Myocardial Infarction 05/2024 - 01/2009
12	Coronary Artery Disease (Coronary Atherosclerosis) 12/2023 - 10/2007
6	Hemorrhage 05/2024 - 01/2020
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 09/2011
6	Pathologic Constriction (Stenosis) 12/2020 - 10/2007
5	ST Elevation Myocardial Infarction 05/2024 - 11/2011
5	Acute Coronary Syndrome 12/2023 - 11/2018
5	Coronary Disease (Coronary Heart Disease) 01/2023 - 10/2007
4	Ischemia 01/2023 - 09/2012
4	Death (Near-Death Experience) 01/2023 - 01/2019
3	Thrombosis (Thrombus) 01/2023 - 01/2021
3	Aortic Valve Stenosis (Aortic Stenosis) 11/2021 - 01/2020
2	Heart Failure 05/2024 - 01/2021
2	Unstable Angina 01/2023 - 11/2011
2	Stable Angina 09/2013 - 11/2011
1	Hyperplasia 01/2023
1	Stroke (Strokes) 01/2023
1	Infarction (Infarctions) 01/2022
1	Myocardial Reperfusion Injury 01/2021
1	Hypothermia 01/2021
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021
1	Coronary Stenosis (Coronary Artery Stenosis) 03/2020
1	Hyperemia 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Hypersensitivity (Allergy) 09/2016
1	Non-ST Elevated Myocardial Infarction 11/2011

Drug/Important Bio-Agent (IBA)

8	omega-Chloroacetophenone (Mace)IBA 01/2022 - 09/2011
5	PolymersIBA 01/2022 - 01/2020
4	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 05/2024 - 10/2021
2	Everolimus FDA Link 01/2023 - 01/2020
2	titanium-nitride-oxideIBA 01/2023 - 01/2020
2	Sirolimus (Rapamycin)FDA Link 08/2022 - 10/2021
2	APTIBA 01/2022 - 10/2021
2	Adenosine (Adenocard)FDA LinkGeneric 01/2020 - 04/2013
1	MetalsIBA 01/2023
1	fexofenadine (Allegra)FDA LinkGeneric 11/2021
1	AnticoagulantsIBA 10/2021
1	IceIBA 01/2021
1	PlatinumIBA 01/2020
1	CobaltIBA 01/2020
1	ChromiumIBA 01/2020
1	von Willebrand FactorIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Antihypertensive Agents (Antihypertensives)IBA 09/2016
1	TroponinIBA 11/2011
1	Creatine Kinase (Creatine Phosphokinase)IBA 11/2011

Therapy/Procedure

19	Percutaneous Coronary Intervention 05/2024 - 01/2009
13	Therapeutics 01/2022 - 09/2012
11	Stents 01/2023 - 10/2007
6	Drug-Eluting Stents 01/2023 - 10/2007
2	Aftercare (After-Treatment) 01/2023 - 11/2018
1	Transcatheter Aortic Valve Replacement 12/2023
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2023
1	Wearable Electronic Devices 01/2020
1	Counterpulsation (External Counterpulsation) 01/2020
1	Length of Stay 11/2011